GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Immunome Inc (NAS:IMNM) » Definitions » 5-Year Dividend Growth Rate

Immunome (Immunome) 5-Year Dividend Growth Rate : 0.00% (As of Dec. 2023)


View and export this data going back to 2020. Start your Free Trial

What is Immunome 5-Year Dividend Growth Rate?

Immunome's Dividends per Share for the three months ended in Dec. 2023 was $0.00.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average dividends per share growth rate.

Immunome's Dividend Payout Ratio for the three months ended in Dec. 2023 was 0.00. As of today, Immunome's Dividend Yield % is 0.00%.

For more information regarding to dividend, please check our Dividend Page.

Competitive Comparison of Immunome's 5-Year Dividend Growth Rate

For the Biotechnology subindustry, Immunome's 5-Year Dividend Growth Rate, along with its competitors' market caps and 5-Year Dividend Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Immunome's 5-Year Dividend Growth Rate Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Immunome's 5-Year Dividend Growth Rate distribution charts can be found below:

* The bar in red indicates where Immunome's 5-Year Dividend Growth Rate falls into.


Immunome 5-Year Dividend Growth Rate Calculation

This is the average annual rate that a company has been raising its dividends. The growth rate is calculated with least square regression.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average dividends per share growth rate.

Immunome  (NAS:IMNM) 5-Year Dividend Growth Rate Explanation

1. Dividend Payout Ratio measures the percentage of the company's earnings paid out as dividends.

Immunome's Dividend Payout Ratio for the quarter that ended in Dec. 2023 is calculated as

Dividend Payout Ratio=Dividends per Share (Q: Dec. 2023 )/ EPS without NRI (Q: Dec. 2023 )
=0/ -2.142
=N/A

2. Dividend Yield % measures how much a company pays out in dividends each year relative to its share price.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Immunome 5-Year Dividend Growth Rate Related Terms

Thank you for viewing the detailed overview of Immunome's 5-Year Dividend Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.

Immunome (Immunome) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Immunome Inc (NAS:IMNM) » Definitions » 5-Year Dividend Growth Rate
Comparable Companies
RNA CGEM MRNS CDMO GHRS GNLX ORTX OCS BMEA RAPT OCSE:NOVO B VRTX REGN ASX:CSL SGEN XKRX:207940 MRNA HKSE:02269 XBRU:ARGX BNTX
Traded in Other Exchanges
N/A
Address
665 Stockton Drive, Suite 300, Exton, PA, USA, 19341
Website
https://www.immunome.com
Immunome Inc is a biopharmaceutical company. It is engaged in utilizing a proprietary human memory B cell platform to discover and develop first-in-class antibody therapeutics designed to change the way diseases are currently being treated. The company's primary focus areas are oncology and infectious disease, including COVID-19. It primarily operates in the U.S. Its current programs comprise Oncology (IMM-ONC-01), SARS-CoV-2 (IMM-BCP-01), and IMM20059 Anti-EPN1.
Executives
Jean Jacques Bienaime director 925 PAGE MILL ROAD, PALO ALTO CA 94304
Robert Lechleider officer: Chief Medical Officer C/O IMMUNOME, INC., 665 STOCKTON DRIVE, SUITE 300 PA 19341
Max Rosett officer: SVP Operations C/O MORPHIMMUNE INC., 101 FOUNDRY DRIVE, SUITE 1200, WEST LAFAYETTE IN 47906
Clay B Siegall director, officer: President and CEO 21823 30TH DR SE, BOTHELL WA 98021
Jack Higgins officer: Chief Scientific Officer C/O MORPHIMMUNE INC., 101 FOUNDRY DRIVE, SUITE 1200, WEST LAFAYETTE IN 47906
Isaac Barchas director, other: See remarks 1601 BRYAN STREET, SUITE 4141, DALLAS TX 75201
Bruce Turner officer: Chief Strategy Officer C/O MORPHIMMUNE INC., 101 FOUNDRY DRIVE, SUITE 1200, WEST LAFAYETTE IN 47906
James P Boylan director C/O ENAVATE SCIENCES, 2884 SAND HILL RD., STE 100, MENLO PARK CA 94025
Matthew K Robinson officer: Chief Technology Officer C/O IMMUNOME, INC., 665 STOCKTON DRIVE SUITE 300, EXTON PA 19341
Michael Rapp director, 10 percent owner 712 FIFTH AVENUE, 49TH FLOOR, NEW YORK NY 10019
Franklyn G Prendergast director
Michael Lefenfeld director IMMUNOME, INC., 665 STOCKTON DRIVE, SUITE 300, EXTON PA 19341
Purnanand D Sarma director, officer: President and CEO IMMUNOME, INC., 665 STOCKTON DRIVE, SUITE 300, EXTON PA 19341
John L Lamattina director 81 WYMAN ST, POST OFFICE BOX 9046, WALTHAM MA 02454
Philip Wagenheim director 712 FIFTH AVENUE, 49TH FLOOR, NEW YORK NY 10019